Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
COPD, FDA and Dupixent
FDA Approves Dupilumab as Add-On for COPD
The US Food and Drug Administration has approved dupilumab as an add-on maintenance therapy for adults whose chronic obstructive pulmonary disease (COPD) is inadequately controlled with inhaler therapy, according to a press release from manufacturer Regeneron.
Sanofi, Regeneron look to seize major opportunity with Dupixent's COPD approval
After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with the progressive disease suddenly have two new options, with more likely o | Regeneron and Sanofi have announced that the FDA has expanded the label of megablockbuster Dupixent to treat COPD.
Dupixent Approved as Add-On Maintenance Therapy in COPD
The approval was supported by data from the 52-week, randomized, double-blind, multicenter, parallel-group, placebo-controlled, phase 3 trials BOREAS and NOTUS.
Sanofi and Regeneron’s allergy drug approved as first biologic for COPD
Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the rating you have given Submit Feedback
FDA Approves Dupixent for Some Patients Struggling With COPD Symptoms
Dupixent may help some people with inadequately controlled COPD who have a type of lung inflammation that worsens symptoms.
FDA Approves Dupilumab as First Biologic Treatment for COPD
The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype to significantly help reduce exacerbations and improve lung function.
Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Dupixent is indicated for the approximately
FDA greenlights Regeneron’s Dupixent for the treatment of COPD
With an approval based on two pivotal Phase III studies, Dupixent is now the first-ever biologic indicated for treating COPD.
Regeneron, Sanofi announce Dupixent approval in China for patients with COPD
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the National Medical Products Administration in China has approved Dupixent as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease characterized by raised blood eosinophils.
Too Old to Operate
3h
Managing Pneumothorax and Emphysema in COPD with Hyperthyroidism and Thyroid Storm
The following is a summary of “Losing Your Breath During the Storm: Spontaneous Pneumothorax and Subcutaneous Emphysema as a ...
Medpage Today on MSN
4d
First-Ever Biologic Approved for COPD
The FDA approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic obstructive pulmonary disease ...
1d
Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024
Ohtuvayre (ensifentrine) is a first-in-class selective dual inhibitor of the enzymes phosphodiesterase three and phosphodiesterase 4 (“PDE3 and PDE4”) that combines bronchodilator and non-steroidal ...
Too Old to Operate
3h
Outcomes of Hospitalization in Patients with COPD Exacerbation and COVID-19 Infection
The following is a summary of "Determining the Impact of COVID-19 Infection on Patients Hospitalized With COPD Exacerbations: ...
pulmonologyadvisor
17h
Dyspnea Impact Worse in People With PRISm vs Undiagnosed Asthma or COPD
In adults with undiagnosed respiratory symptoms, dyspnea impact was worse in those with PRISm vs undiagnosed asthma or COPD.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Dupixent
China
Regeneron
United States
Chronic obstructive pulmonary disease
Feedback